Key facts
- This page summarizes John A. Stalfort III's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Nov 2024, 16:15.
John A. Stalfort III - 22 Nov 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)
- Reporting relationship
- Director
- Issuer ticker
- VRCA
- Reported as of
- 22 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Nov 2024, 16:15:08 UTC
- Prior SEC filing
- 10 Jun 2024
- Next SEC filing
- 04 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John A. Stalfort III filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 26 Nov 2024.
Change
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRCA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,123,595
- Change %
- +160%
- Price
- Shares after
- 1,823,800
- Date
- 22 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
VRCA
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +2.7%
- Price
- $0.000000
- Shares after
- 1,873,800
- Date
- 26 Nov 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRCA
transaction
Derivative
Series A Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +561,797
- Change %
- Price
- Shares after
- 561,797
- Date
- 22 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 561,797
- Exercise price
- $1.07
- Footnotes
- F1
VRCA
transaction
Derivative
Series B Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +561,797
- Change %
- Price
- Shares after
- 561,797
- Date
- 22 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 561,797
- Exercise price
- $1.34
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.